Svennevig K - Search Results

1

Alterations in regulators of the extracellular matrix in non-Hodgkin lymphomas.

Negaard HF, Svennevig K, Kolset SO, Iversen N, Lothe IM, Østenstad B, Sandset PM, Iversen PO. Negaard HF, et al. Among authors: svennevig k. Leuk Lymphoma. 2009 Jun;50(6):998-1004. doi: 10.1080/10428190902889270. Leuk Lymphoma. 2009. PMID: 19373600

2

Associations between regulators of extracellular matrix and hemostatic factors in hematologic neoplasias.

Negaard HF, Sandset PM, Kolset SO, Svennevig K, Østenstad B, Iversen PO. Negaard HF, et al. Among authors: svennevig k. Leuk Lymphoma. 2011 Jun;52(6):1157-9. doi: 10.3109/10428194.2011.563886. Epub 2011 Apr 4. Leuk Lymphoma. 2011. PMID: 21463121 No abstract available.

3

Matrix metalloproteinases in subjects with type 1 diabetes.

Gharagozlian S, Svennevig K, Bangstad HJ, Winberg JO, Kolset SO. Gharagozlian S, et al. Among authors: svennevig k. BMC Clin Pathol. 2009 Sep 16;9:7. doi: 10.1186/1472-6890-9-7. BMC Clin Pathol. 2009. PMID: 19758433 Free PMC article.

4

Proteoglycans in polarized epithelial Madin-Darby canine kidney cells.

Svennevig K, Prydz K, Kolset SO. Svennevig K, et al. Biochem J. 1995 Nov 1;311 ( Pt 3)(Pt 3):881-8. doi: 10.1042/bj3110881. Biochem J. 1995. PMID: 7487945 Free PMC article.

5

Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1.

Meen AJ, Øynebråten I, Reine TM, Duelli A, Svennevig K, Pejler G, Jenssen T, Kolset SO. Meen AJ, et al. Among authors: svennevig k. J Biol Chem. 2011 Jan 28;286(4):2636-47. doi: 10.1074/jbc.M110.151944. Epub 2010 Nov 12. J Biol Chem. 2011. PMID: 21075844 Free PMC article.

6

Increased syndecan-1 in serum is related to early nephropathy in type 1 diabetes mellitus patients.

Svennevig K, Kolset SO, Bangstad HJ. Svennevig K, et al. Diabetologia. 2006 Sep;49(9):2214-6. doi: 10.1007/s00125-006-0330-4. Epub 2006 Jul 11. Diabetologia. 2006. PMID: 16832664 No abstract available.

7

Biocompatibility and pathways of initial complement pathway activation with Phisio- and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery.

Thiara AS, Mollnes TE, Videm V, Andersen VY, Svennevig K, Kolset SO, Fiane AE. Thiara AS, et al. Among authors: svennevig k. Perfusion. 2011 Mar;26(2):107-14. doi: 10.1177/0267659110392438. Epub 2010 Dec 22. Perfusion. 2011. PMID: 21177724 Clinical Trial.

8

Syndecan-1 plasma levels during coronary artery bypass surgery with and without cardiopulmonary bypass.

Svennevig K, Hoel T, Thiara A, Kolset S, Castelheim A, Mollnes T, Brosstad F, Fosse E, Svennevig J. Svennevig K, et al. Among authors: svennevig j. Perfusion. 2008 May;23(3):165-71. doi: 10.1177/0267659108098215. Perfusion. 2008. PMID: 19029267

9

Comparable biocompatibility of Phisio- and Bioline-coated cardiopulmonary bypass circuits indicated by the inflammatory response.

Thiara AS, Andersen VY, Videm V, Mollnes TE, Svennevig K, Hoel TN, Fiane AE. Thiara AS, et al. Among authors: svennevig k. Perfusion. 2010 Jan;25(1):9-16. doi: 10.1177/0267659110362822. Epub 2010 Feb 19. Perfusion. 2010. PMID: 20172900 Clinical Trial.

10

The difference between drugs and nutritional supplements.

Svennevig K. Svennevig K. Tidsskr Nor Laegeforen. 2011 Jun 3;131(11):1074-5. doi: 10.4045/tidsskr.11.0167. Tidsskr Nor Laegeforen. 2011. PMID: 21681232 Free article. English, Norwegian. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters